High-dose etoposide (VP-16) in small-cell lung cancer

F. A. Greco, D. H. Johnson, K. R. Hande, L. L. Porter, J. D. Hainsworth, S. N. Wolff

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Etoposide (VP-16) is one of the most active drugs against small-cell lung cancer. There may be a steep dose-response relationship, and we have explored the use of etoposide as a single agent in a high dose (1,200 mg/m2) without bone marrow transplantation, for patients with very bulky, extensive-stage disease. This therapy is well tolerated in patients having good performance status, with myelosuppression representing the major toxicity. Our data suggest there may truly be a steep dose-response relationship. We have continued to explore intensive induction therapy for selected very poor-prognosis patients by adding high-dose cyclophosphamide (100 mg/kg) to high-dose etoposide. This combination is also very myelotoxic, but quite similar to etoposide alone. Our current study adds cisplatin (120 mg/m2) to the high-dose cyclophosphamide-etoposide schedule in an attempt to take advantage of the synergism seen with these drugs in various other circumstances. This series of studies will give us information regarding the feasibility of intensive induction therapy and provide data for the design of phase III studies.

Original languageEnglish (US)
Pages (from-to)42-44
Number of pages3
JournalSeminars in Oncology
Volume12
Issue number1 SUPPL. 2
StatePublished - 1985

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Cyclophosphamide
Bone Marrow Transplantation
Pharmaceutical Preparations
Cisplatin
Appointments and Schedules
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Greco, F. A., Johnson, D. H., Hande, K. R., Porter, L. L., Hainsworth, J. D., & Wolff, S. N. (1985). High-dose etoposide (VP-16) in small-cell lung cancer. Seminars in Oncology, 12(1 SUPPL. 2), 42-44.

High-dose etoposide (VP-16) in small-cell lung cancer. / Greco, F. A.; Johnson, D. H.; Hande, K. R.; Porter, L. L.; Hainsworth, J. D.; Wolff, S. N.

In: Seminars in Oncology, Vol. 12, No. 1 SUPPL. 2, 1985, p. 42-44.

Research output: Contribution to journalArticle

Greco, FA, Johnson, DH, Hande, KR, Porter, LL, Hainsworth, JD & Wolff, SN 1985, 'High-dose etoposide (VP-16) in small-cell lung cancer', Seminars in Oncology, vol. 12, no. 1 SUPPL. 2, pp. 42-44.
Greco FA, Johnson DH, Hande KR, Porter LL, Hainsworth JD, Wolff SN. High-dose etoposide (VP-16) in small-cell lung cancer. Seminars in Oncology. 1985;12(1 SUPPL. 2):42-44.
Greco, F. A. ; Johnson, D. H. ; Hande, K. R. ; Porter, L. L. ; Hainsworth, J. D. ; Wolff, S. N. / High-dose etoposide (VP-16) in small-cell lung cancer. In: Seminars in Oncology. 1985 ; Vol. 12, No. 1 SUPPL. 2. pp. 42-44.
@article{53fddc2674fc45aa86ada8314d386911,
title = "High-dose etoposide (VP-16) in small-cell lung cancer",
abstract = "Etoposide (VP-16) is one of the most active drugs against small-cell lung cancer. There may be a steep dose-response relationship, and we have explored the use of etoposide as a single agent in a high dose (1,200 mg/m2) without bone marrow transplantation, for patients with very bulky, extensive-stage disease. This therapy is well tolerated in patients having good performance status, with myelosuppression representing the major toxicity. Our data suggest there may truly be a steep dose-response relationship. We have continued to explore intensive induction therapy for selected very poor-prognosis patients by adding high-dose cyclophosphamide (100 mg/kg) to high-dose etoposide. This combination is also very myelotoxic, but quite similar to etoposide alone. Our current study adds cisplatin (120 mg/m2) to the high-dose cyclophosphamide-etoposide schedule in an attempt to take advantage of the synergism seen with these drugs in various other circumstances. This series of studies will give us information regarding the feasibility of intensive induction therapy and provide data for the design of phase III studies.",
author = "Greco, {F. A.} and Johnson, {D. H.} and Hande, {K. R.} and Porter, {L. L.} and Hainsworth, {J. D.} and Wolff, {S. N.}",
year = "1985",
language = "English (US)",
volume = "12",
pages = "42--44",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 2",

}

TY - JOUR

T1 - High-dose etoposide (VP-16) in small-cell lung cancer

AU - Greco, F. A.

AU - Johnson, D. H.

AU - Hande, K. R.

AU - Porter, L. L.

AU - Hainsworth, J. D.

AU - Wolff, S. N.

PY - 1985

Y1 - 1985

N2 - Etoposide (VP-16) is one of the most active drugs against small-cell lung cancer. There may be a steep dose-response relationship, and we have explored the use of etoposide as a single agent in a high dose (1,200 mg/m2) without bone marrow transplantation, for patients with very bulky, extensive-stage disease. This therapy is well tolerated in patients having good performance status, with myelosuppression representing the major toxicity. Our data suggest there may truly be a steep dose-response relationship. We have continued to explore intensive induction therapy for selected very poor-prognosis patients by adding high-dose cyclophosphamide (100 mg/kg) to high-dose etoposide. This combination is also very myelotoxic, but quite similar to etoposide alone. Our current study adds cisplatin (120 mg/m2) to the high-dose cyclophosphamide-etoposide schedule in an attempt to take advantage of the synergism seen with these drugs in various other circumstances. This series of studies will give us information regarding the feasibility of intensive induction therapy and provide data for the design of phase III studies.

AB - Etoposide (VP-16) is one of the most active drugs against small-cell lung cancer. There may be a steep dose-response relationship, and we have explored the use of etoposide as a single agent in a high dose (1,200 mg/m2) without bone marrow transplantation, for patients with very bulky, extensive-stage disease. This therapy is well tolerated in patients having good performance status, with myelosuppression representing the major toxicity. Our data suggest there may truly be a steep dose-response relationship. We have continued to explore intensive induction therapy for selected very poor-prognosis patients by adding high-dose cyclophosphamide (100 mg/kg) to high-dose etoposide. This combination is also very myelotoxic, but quite similar to etoposide alone. Our current study adds cisplatin (120 mg/m2) to the high-dose cyclophosphamide-etoposide schedule in an attempt to take advantage of the synergism seen with these drugs in various other circumstances. This series of studies will give us information regarding the feasibility of intensive induction therapy and provide data for the design of phase III studies.

UR - http://www.scopus.com/inward/record.url?scp=0021978723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021978723&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 42

EP - 44

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 2

ER -